Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Disruption of human papillomavirus 16 E6 gene by clustered regularly interspaced short palindromic repeat/Cas system in human cervical cancer cells [Corrigendum]
Yu L, Wang XL, Zhu D, Ding WC, Wang LM, Zhang CL, Jiang XH, Shen H, Liao SJ, Ma D, Hu Z, Wang H
Published Date: 4 February 2015
Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
Published Date: 23 December 2014
Racial differences in tumor necrosis factor-α-induced endothelial microparticles and interleukin-6 production
Brown MD, Feairheller DL, Thakkar S, Veerabhadrappa P, Park JY
Published Date: 26 August 2011
Davide Capodanno, Fabio Dipasqua, Corrado Tamburino
Published Date: 25 February 2011
Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
Peter Alagona Jr
Published Date: 13 May 2010
Jeremy A Falk, Kiran J Philip, Ernst R Schwarz
Published Date: 20 April 2010
Yoshiko Ohno, Teruto Hashiguchi, Ryuichi Maenosono, et al
Published Date: 9 March 2010
Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou
Published Date: 16 February 2010
Eduardo Pimenta, Suzanne Oparil
Published Date: 19 May 2009
Managing hypercholesterolemia and its correlation with carotid plaque morphology in patients undergoing carotid endarterectomy
Kittipan Rerkasem, Patrick J Gallagher, Robert F Grimble, Philip C Calder, Clifford P Shearman
Published Date: 12 September 2008